Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer’s disease

References

• Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science217(4558), 408–414 (1982).
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science256(5054), 184–185 (1992).
   PubMed Web of Science ®Google Scholar
• Rogaev EI, Sherrington R, Rogaeva EA et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature376(6543), 775–778 (1995).
   PubMed Web of Science ®Google Scholar
• Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature375(6534), 754–760 (1995).
   PubMed Web of Science ®Google Scholar
• Citron M, Westaway D, Xia W et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med.3(1), 67–72 (1997).
   PubMed Web of Science ®Google Scholar
• Cognex®, Package insert. Cayman Chemical Company, MI, USA.
   Google Scholar
• Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol. Sci.26(2), 104–111 (2005).
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Farlow MR, Relkin NR et al. Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? Alzheimers Dement.2, 118–125 (2006).
   PubMedGoogle Scholar
• Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis. Assoc. Disord.20(2 Suppl.1), S8–S11 (2006).
   PubMed Web of Science ®Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis. Assoc. Disord.20(2 Suppl.1), S12–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Mori E, Hashimoto M, Krishnan KR, Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis. Assoc. Disord.20(2 Suppl.1), S19–S26 (2006).
   PubMed Web of Science ®Google Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD001190 (2006).
   PubMedGoogle Scholar
• Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev.3, CD006104 (2006).
   Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.1, CD001747 (2006).
   Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev.4, CD001191 (2000).
   PubMedGoogle Scholar
• Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol.58(3), 427–433 (2001).
   PubMed Web of Science ®Google Scholar
• Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur. Neurol.44(4), 236–241 (2000).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology54(12), 2261–2268 (2000).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol.10(3), 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord.21(5–6), 353–363 (2006).
   PubMed Web of Science ®Google Scholar
• Bencherif B, Endres CJ, Musachio JL et al. PET imaging of brain acetylcholinesterase using 11C CP-126,998, a brain selective enzyme inhibitor. Synapse45(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Bickel U, Thomsen T, Weber W et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol. Ther.50(4), 420–428 (1991).
   PubMed Web of Science ®Google Scholar
• Cutler NR, Polinsky RJ, Sramek JJ et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol. Scand.97(4), 244–250 (1998).
   PubMed Web of Science ®Google Scholar
• Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease? CNS Drugs.15(2), 85–91 (2001).
   PubMed Web of Science ®Google Scholar
• Almkvist O, Jelic V, Amberla K, Hellström-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement. Geriatr. Cogn. Disord.12(1), 22–32 (2001).
   PubMed Web of Science ®Google Scholar
• Goekoop R, Rombouts SA, Jonker C et al. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage23(4), 1450–1459 (2004).
   PubMed Web of Science ®Google Scholar
• Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow wave power in Alzheimer patients. Neuropsychobiology43(4), 273–276 (2001).
   PubMed Web of Science ®Google Scholar
• Brassen S, Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry36(6), 304–308 (2003).
   PubMed Web of Science ®Google Scholar
• Adler G, Brassen S, Chwalek K, Dieter B, Teufel M. Prediction of treatment response to rivastigmine in Alzheimer’s dementia. J. Neurol. Neurosurg. Psychiatry75(2), 292–294 (2004).
   PubMed Web of Science ®Google Scholar
• Johannsen P, Salmon E, Hampel H et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs20(4), 311–325 (2006).
   PubMed Web of Science ®Google Scholar
• Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology63(4), 651–657 (2004).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. Neurol.55, 815–828 (2004).
   PubMed Web of Science ®Google Scholar
• Davis KL, Mohs RC, Marin D et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA281(15), 1401–1406 (1999).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Ikonomovic MD, Styren SD et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol.51(2), 145–155 (2002).
   PubMed Web of Science ®Google Scholar
• Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am. J. Alzheimers Dis. Other Demen.20(5), 295–302 (2005).
   PubMedGoogle Scholar
• Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363(9427), 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Almkvist O, Darreh-Shori T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer’s disease in comparison with untreated AD and MCI patients. Eur. J. Neurol.11(4), 253–261 (2004).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Small GW, Hammond G, van Baelen B, Schwalen S. Effects of galantamine in patients with mild Alzheimer’s disease. Curr. Med. Res. Opin.20(11), 1815–1820 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Seltzer B, Zolnouni P, Nunez M et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch. Neurol.61(12), 1852–1856 (2004).
   PubMed Web of Science ®Google Scholar
• Masliah E, Alford M, Adame A et al. Aβ1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology61(2), 206–211 (2003).
   PubMed Web of Science ®Google Scholar
• Carroll RT, Lust MR, Emmerling MR. β-amyloid levels predict cholinesterase activity in human cerebrospinal fluid. Neuroreport10(1), 127–130 (1999).
   PubMed Web of Science ®Google Scholar
• Sarter M, Bruno JP. Mild cognitive impairment and the cholinergic hypothesis: a very different take on recent data. Ann. Neurol.52(3), 384–385 (2002).
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Garlind A, O’Neill C, Cowburn RF. Receptor–effector coupling dysfunctions in Alzheimer’s disease. Ann. NY Acad. Sci.786, 294–304 (1996).
   PubMed Web of Science ®Google Scholar
• Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW. Donepezil in the treatment of dementia with Lewy bodies. Am. J. Geriatr. Psychiatry12(5), 542–544 (2004).
   PubMed Web of Science ®Google Scholar
• Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Dementia with lewy bodies: findings from an international multicentre study. Int. J. Geriatr. Psychiatry15(11), 1034–1045 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in down syndrome. Am. J. Ment. Retard.108(6), 367–372 (2003).
   PubMedGoogle Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356(9247), 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease – pilot study. Int. J. Geriatr. Psychiatry17(3), 270–278 (2002).
   PubMed Web of Science ®Google Scholar
• Wesnes KA, McKeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement. Geriatr. Cogn. Disord.13(3), 183–192 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18(10), 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry72(6), 708–712 (2002).
   PubMed Web of Science ®Google Scholar
• Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J. Geriatr. Psychiatry Neurol.16(3), 184–188 (2003).
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry19(1), 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Lasa A, Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin. Neuropharmacol.28(4), 176–178 (2005).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine–acetylcholine synaptic balance. Lancet Neurol.5(11), 974–983 (2006).
   PubMed Web of Science ®Google Scholar
• Black S, Roman GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke34(10), 2323–2330 (2003).
   PubMed Web of Science ®Google Scholar
• Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol. Psychiatry45(8), 959–964 (1999).
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov. Disord.19(12), 1516–1518 (2004).
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet359(9314), 1283–1290 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington’s disease. Mov. Disord.15(1), 173–176 (2000).
   PubMed Web of Science ®Google Scholar
• Hoopes SP. Donepezil for Tourette’s disorder and ADHD. J. Clin. Psychopharmacol.19(4), 381–382 (1999).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology63, 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Morey CE, Cilo M, Berry J, Cusick C. The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj.17(9), 809–815 (2003).
   PubMed Web of Science ®Google Scholar
• Parry AM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain126(Pt 12), 2750–2760 (2003).
   PubMed Web of Science ®Google Scholar
• Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj.12(1), 77–80 (1998).
   PubMed Web of Science ®Google Scholar
• Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Prog. Neuropsychopharmacol. Biol. Psychiatry29(1), 61–67 (2005).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J. Child Adolesc. Psychopharmacol.10(3), 217–222 (2000).
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Doody R, Helme R et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology61(4), 479–486 (2003).
   PubMed Web of Science ®Google Scholar
• Svensson AL, Nordberg A. Interaction of tacrine, galanthamine, NXX-066 and E2020 with neurol α4β2 nicotinic receptors expressed in fibroblast cells. In: Alzheimer’s Disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B, Nishimura T et al. (Eds). Wiley & Sons, NY, USA, 751–756 (1997).
   Google Scholar
• Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology51(3), 474–486 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience99(1), 17–23 (2000).
   PubMed Web of Science ®Google Scholar
• Reid RT, Sabbagh MN. Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J. Alzheimers Dis.5(6), 429–436 (2003).
   PubMed Web of Science ®Google Scholar
• Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci. Lett.260(1), 5–8 (1999).
   PubMed Web of Science ®Google Scholar
• Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT. Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J. Pharmacol. Exp. Ther.317, 606–614 (2006).
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. Anti-amnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide (CO) gas. J. Pharmacol. Exp. Ther.317(3), 1307–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther.315(3), 1346–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25–35) in rat PC12 cells. Neuroreport9(7), 1519–1522 (1998).
   PubMed Web of Science ®Google Scholar
• Kimura M, Akasofu S, Ogura H, Sawada K. Protective effect of donepezil against Aβ(1-40) neurotoxicity in rat septal neurons. Brain Res.1047(1), 72–84 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and memantine for protective effect against amyloid-β(1-42) toxicity in rat septal neurons. Neurosci. Lett.391(1–2), 17–21 (2005).
   PubMed Web of Science ®Google Scholar
• Giacobini E, Zhu XD, Williams E, Sherman KA. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology35(2), 205–211 (1996).
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Volterrani D, Tognoni G et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin. Neuropharmacol.27(4), 166–170 (2004).
   PubMed Web of Science ®Google Scholar
• Nobili F, Vitali P, Canfora M et al. Effects of long-term donepezil therapy on rCBF of Alzheimer’s patients. Clin. Neurophysiol.113(8), 1241–1248 (2002).
   PubMed Web of Science ®Google Scholar
• Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer’s disease receiving donepezil therapy. Nucl. Med. Commun.21(1), 37–41 (2000).
   PubMed Web of Science ®Google Scholar
• Venneri A, Shanks MF, Staff RT et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease. Neuroreport13(1), 83–87 (2002).
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur. J. Pharmacol.472(1–2), 57–63 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ogawa N, Mizukawa K et al. Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochem. Res.19(2), 117–122 (1994).
   PubMed Web of Science ®Google Scholar
• Wang XD, Chen XQ, Yang HH, Hu GY. Comparison of the effects of cholinesterase inhibitors on 3H MK-801 binding in rat cerebral cortex. Neurosci. Lett.272(1), 21–24 (1999).
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kimura M, Kosasa T, Ogura H, Sawada K. Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-D-aspartate (NMDA) toxicity. Eur. J. Pharmacol.530(3), 215–222 (2006).
   PubMed Web of Science ®Google Scholar
• Gambi F, Reale M, Iarlori C et al. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol.24(3), 314–321 (2004).
   PubMed Web of Science ®Google Scholar
• Pollak Y, Gilboa A, Ben-Menachem O, Ben Hur T, Soreq H, Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1β production. Ann. Neurol.57(5), 741–745 (2005).
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The acetylcholinesterase inhibitor, donepezil, regulates a Th2 bias in Alzheimer’s disease patients. Neuropharmacology50(5), 606–613 (2006).
   PubMed Web of Science ®Google Scholar
• Nobili F, Koulibaly M, Vitali Pet al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J. Nucl. Med.43(8), 983–990 (2002).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Namiki C, Thuy DH et al. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J. Neurol Sci.255(1–2), 135–141 (2006).
   Google Scholar
• Hoyer S. Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol. Chem. Neuropathol.16(3), 207–224 (1992).
   PubMedGoogle Scholar
• Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology47(2), 454–461 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy DG, Bottomley PA, Salerno JA et al. An in vivo study of phosphorus and glucose metabolism in Alzheimer’s disease using magnetic resonance spectroscopy and PET. Arch. Gen. Psychiatry50(5), 341–349 (1993).
   PubMed Web of Science ®Google Scholar
• Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer’s disease correlates with progressive metabolic impairment of association areas. Dementia5(1), 36–41 (1994).
   PubMedGoogle Scholar
• Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer’s disease. Clin. Positron Imaging2(3), 119–130 (1999).
   PubMedGoogle Scholar
• Small GW. Brain-imaging surrogate markers for detection and prevention of age-related memory loss. J. Mol. Neurosci.19(1–2), 17–21 (2002).
   PubMed Web of Science ®Google Scholar
• Moeller JR, Rusinek H, Casanova MF et al. Donepezil maintains activity in a specific neural network in patients with Alzheimer’s disease. Eur. J. Neurol.10(Suppl. 1), P2102 (2003).
   Google Scholar
• Tune L, Tiseo PJ, Ieni J et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry11(2), 169–177 (2003).
   PubMed Web of Science ®Google Scholar
• Stefanova E, Blennow K, Almkvist O, Hellström-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1-42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci. Lett.338(2), 159–163 (2003).
   PubMed Web of Science ®Google Scholar
• Stefanova E, Wall A, Almkvist O et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. J. Neural Transm.113(2), 205–218 (2006).
   PubMed Web of Science ®Google Scholar
• Jessen F, Block W, Traber F et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology57(5), 930–932 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol.46(5), 531–540 (1995).
   PubMed Web of Science ®Google Scholar
• Jaarsma D, Veenma-van der Duin L, Korf J. N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer’s disease post-mortem brain tissue. J. Neurol. Sci.127(2), 230–233 (1994).
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Charles HC, Doraiswamy PM et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am. J. Psychiatry160(11), 2003–2011 (2003).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Dickson DW, Parisi JE et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology58(5), 750–757 (2002).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Petersen RC, Xu Y et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology55(4), 484–489 (2000).
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am. J. Psychiatry162(4), 676–682 (2005).
   PubMed Web of Science ®Google Scholar
• Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol.55(7), 937–945 (1998).
   PubMedGoogle Scholar
• Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and A β1-42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol.44(1), 17–26 (1998).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol.26(3), 231–245 (1995).
   PubMedGoogle Scholar
• Di Luca M, Pastorino L, Cattabeni F et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch. Neurol.53(11), 1162–1166 (1996).
   PubMedGoogle Scholar
• Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development – a study of molecular forms. Neurochem. Int.21(3), 381–396 (1992).
   PubMed Web of Science ®Google Scholar
• Parnetti L, Amici S, Lanari A et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol. Sci.23(Suppl. 2), S95–S96 (2002).
   PubMed Web of Science ®Google Scholar
• Borroni B, Colciaghi F, Pastorino L et al. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur. Neuropsychopharmacol.12(3), 195–200 (2002).
   PubMed Web of Science ®Google Scholar
• Borroni B, Colciaghi F, Pastorino L et al. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch. Neurol.58(3), 442–446 (2001).
   PubMedGoogle Scholar
• Liu HC, Chi CW, Ko SY et al. Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.19(5–6), 345–348 (2005).
   PubMed Web of Science ®Google Scholar
• Sternfeld M, Shoham S, Klein O et al. Excess ‘read-through’ acetylcholinesterase attenuates but the ‘synaptic’ variant intensifies neurodeterioration correlates. Proc. Natl Acad. Sci. USA97(15), 8647–8652 (2000).
   PubMed Web of Science ®Google Scholar
• Meshorer E, Erb C, Gazit R et al. Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science295(5554), 508–512 (2002).
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Hellström-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer’s disease patients. J. Neurochem.88(5), 1102–1113 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging21(7), 453–478 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez A, Bronfman F, Perez CA, Vicente M, Garrido J, Inestrosa NC. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides. Neurosci. Lett.201(1), 49–52 (1995).
   PubMed Web of Science ®Google Scholar
• Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol.65(3), 407–416 (2003).
   PubMed Web of Science ®Google Scholar
• Verhoeff NP. Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer’s disease. Expert Rev. Neurother.5(2), 277–284 (2005).
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Dinamarca MC, Perez-Acle T, Colombres M. Acetylcholinesterase-amyloid-β-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr. Alzheimer Res.2(3), 301–306 (2005).
   PubMedGoogle Scholar
• Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.20(2–3), 120–132 (2005).
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology57(3), 481–488 (2001).
   PubMed Web of Science ®Google Scholar
• Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicenter trial. Eur. J. Neurol.11(11), 734–741 (2004).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol.61(2), 252–256 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology50(1), 136–145 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia7(6), 293–303 (1996).
   PubMedGoogle Scholar
• Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br. Med. J.318(7184), 633–638 (1999).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology54(12), 2269–2276 (2000).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br. Med. J.321(7274), 1445–1449 (2000).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am. J. Geriatr. Pharmacother.3(3), 137–148 (2005).
   PubMedGoogle Scholar
• Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease (published erratum appears in Neurology 57(11), 2153 [2001]). Neurology57(4), 613–620 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int. J. Geriatr. Psychiatry20(6), 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J. Am. Geriatr. Soc.49(12), 1590–1599 (2001).
   PubMed Web of Science ®Google Scholar
• Takada Y, Yonezawa A, Kume T et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther.306(2), 772–777 (2003).
   PubMed Web of Science ®Google Scholar
• AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial, Lancet363, 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar